Cancer epidemiology

Each year globally, over 14 million incident cancers are diagnosed, and over 8 million people die from cancer. Cancer incidence has increased over the past number of decades and is estimated to continue this increase exceeding 23 million incident cancers worldwide by 2030. Cancer epidemiology is the study of distribution and determinants of cancer incidence and prognosis.

Cancer research at DCE focuses on the risk of cancer, and the prognosis and complications in relation to medical and surgical treatment among cancer patients. Of special interest are cancers of breast, digestive organs, and urinary tract.

We are currently conducting studies on the effect of prescription drugs (e.g., polypharmacy), comorbid diseases (e.g., diabetes), and genetic and molecular factors (e.g., genetic polymorphisms and biomarkers) on the risk and prognosis of breast cancer. We also do descriptive studies on breast cancer incidence and survival trends. New lines of research in breast cancer include genetic screening for familial mutations and the impact of population-based mammography screening on trends in breast cancer incidence and mortality.

Within the field of gastrointestinal cancer, we study prognosis among cancer patients in relation to venous thromboembolism and other complications. Our research in urinary tract cancer focuses on the impact of comorbidity and other patient characteristic on prognosis (please see the Urologic diseases page).

 

Selected DCE publications


Contact

Deirdre Cronin Fenton

Associate professor, BSc, PhD
M
P +4587168209

Henrik Toft Sørensen

Clinical professor and chair, MD, PhD, DMSc
M
P +4587168215